Trial · NCT04665570
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change in HbA1c | From baseline to end of week 24 | HbA1c: Glycated Hemoglobin |
| Secondary | Change in HbA1c | From baseline to end of week 12 | |
| Secondary | Change in fasting blood glucose | From baseline to end of week 6, week 12, week 24 | |
| Secondary | Change in postprandial glucose level | From baseline to end of week 6, week 12, week 24 | |
| Secondary | Occurrence of Hypoglycemic events | From baseline up to 24 weeks | |
| Secondary | Severity of Hypoglycemic events | From baseline up to 24 weeks | |
| Secondary | Occurrence of Gastrointestinal intolerance | From baseline up to 24 weeks | |
| Secondary | Occurrence of other AEs relating to tolerability | From baseline up to 24 weeks | |
| Secondary | Change in patient tolerability to therapy | From baseline up to 24 weeks | |
| Secondary | Mean change in body weight | From baseline to end of week 12, week 24 | |
| Secondary | Mean change in lipid profile | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of starting dose and final dosing | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of time taken for full dose titration | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of PPG recorded at each visit | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of FBG recorded at each visit | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of HbA1c recorded at each visit | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of body weight recorded at each visit | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of actual duration of treatment with acarbose/metformin FDC before addition of other anti-diabetes drugs | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of time of addition of the other anti-diabetes drug | From baseline up to 24 weeks | |
| Secondary | Descriptive analysis of reason of addition of the other anti-diabetes drug | From baseline up to 24 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04665570/registered